Ignacio
Gil Bazo
Investigador hasta 2022
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (6)
2024
-
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
Molecular Cancer, Vol. 23, Núm. 1
2023
-
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
Frontiers in Immunology, Vol. 14
-
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Thrombosis Research, Vol. 232, pp. 133-137
-
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
Journal of Translational Medicine, Vol. 21, Núm. 1
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
-
Tratamiento actual del cáncer de pulmón de células no pequeñas con mutación de EGFR: primera línea y manejo a la progression
Revisiones en Cancer, Vol. 37, Núm. 4, pp. 169-179